Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABO 202

Next Previous
Drug Profile

ABO 202

Alternative Names: AAV-CLN1 - Abeona Therapeutics; ABO-202; scAAV-CLN1; TSHA-118

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Edinburgh; University of North Carolina at Chapel Hill
  • Developer Abeona Therapeutics; Taysha Gene Therapies; University of North Carolina at Chapel Hill
  • Class Gene therapies
  • Mechanism of Action Gene transference; Palmitoyl-protein thioesterase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuronal ceroid lipofuscinosis
  • New Molecular Entity No

Highest Development Phases

  • Suspended Neuronal ceroid lipofuscinosis

Most Recent Events

  • 18 Mar 2024 Abeona Therapeutics has patents pending for 'optimized CLN1 genes and expression cassettes for use in treating CLN1 disease' and 'treating CLN1 disease using a combination of intrathecal and intravenous administrations' in the US, Europe and other geographical regions
  • 10 May 2023 Suspended - Phase-I/II for Neuronal ceroid lipofuscinosis in Canada (IV) due to limited financial and management resources
  • 10 May 2023 Suspended - Phase-I/II for Neuronal ceroid lipofuscinosis in USA (IV) due to limited financial and management resources
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top